Search research articles
Contact Us
Filters
Showing results (21-30 of 35) with videos related to
Page
of 4
Sort By:
South Asian Journal of Cancer
|
December 22, 2025
High-Grade Gastrointestinal Neuroendocrine Carcinomas: Multidisciplinary Approach Can Improve Survival Outcomes
Noorzia Syed, Anant Ramaswamy, Aditya Dhanawat, et al.
Research Square
|
March 3, 2023
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Blood Cancer Journal
|
July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Nature Communications
|
August 12, 2021
ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer
Rokana Taftaf, Xia Liu, Salendra Singh, et al.
Blood Neoplasia
|
June 27, 2025
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience
Malin Hultcrantz, Andriy Derkach, Hani Hassoun, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies
Issam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 25, 2020
COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
Malin Hultcrantz, Joshua Richter, Cara Rosenbaum, et al.
JCO Oncology Practice
|
September 16, 2025
Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses
Issam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.
Blood Advances
|
April 10, 2024
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
Issam S Hamadeh, Tala Shekarkhand, Colin Rueda, et al.
Blood Advances
|
October 25, 2023
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
Ross S Firestone, Devin McAvoy, Tala Shekarkhand, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 35) with videos related to
Sort By:
Page
of 4
South Asian Journal of Cancer
|
December 22, 2025
High-Grade Gastrointestinal Neuroendocrine Carcinomas: Multidisciplinary Approach Can Improve Survival Outcomes
Noorzia Syed, Anant Ramaswamy, Aditya Dhanawat, et al.
Research Square
|
March 3, 2023
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Blood Cancer Journal
|
July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Nature Communications
|
August 12, 2021
ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer
Rokana Taftaf, Xia Liu, Salendra Singh, et al.
Blood Neoplasia
|
June 27, 2025
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience
Malin Hultcrantz, Andriy Derkach, Hani Hassoun, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies
Issam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 25, 2020
COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
Malin Hultcrantz, Joshua Richter, Cara Rosenbaum, et al.
JCO Oncology Practice
|
September 16, 2025
Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses
Issam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.
Blood Advances
|
April 10, 2024
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
Issam S Hamadeh, Tala Shekarkhand, Colin Rueda, et al.
Blood Advances
|
October 25, 2023
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
Ross S Firestone, Devin McAvoy, Tala Shekarkhand, et al.
Page
of 4